CymaBay Therapeutics, Inc. (CBAY) Stock: Seeing Declines In Today’s Session

0
47
Rand Capital Corporation RAND Stock News

CymaBay Therapeutics, Inc. (CBAY) is falling in the market in today’s trading session. The company, focused on the biotech space, is presently priced at $6.05 after tumbling -45.45% so far today. In terms of biotechnology companies, there are quite a few aspects that have the ability to generate declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines centered around CBAY:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-11-19 12:25PM Here’s Why CymaBay Therapeutics Collapsed Today
09:02AM How Much Are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Insiders Spending On Buying Shares?
08:58AM CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors
08:30AM CymaBay Therapeutics Plummets 40% Following Liver Disease Data
07:00AM CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

However, when making a decision with regard to investing, investors should focus on much more than just news, this is especially the case in the speculative biotech sector. Here’s what’s going on with CymaBay Therapeutics, Inc..

Recent Movement From CBAY

While a move toward the top in a single session, like what we’re seeing from CymaBay Therapeutics, Inc. might make some investors fearful, a single session move by itself should not be the basis of a decision to, or not to, buy a company’s stock. It’s always important to dig into trends beyond a single session. When it comes to CBAY, below are the movements that we’ve seen:

  • Past 7 Days – In the last 7 days, CBAY has produced a change in value in the amount of -50.97%.
  • Past 30 Days – The return on investment from CymaBay Therapeutics, Inc. in the last 30 days has been -53.46%.
  • Past Three Months – Over the past quarter, the company has produced a return that works out to -54.75%
  • Bi-Annually – In the past six months, we’ve seen a performance that amounts to -29.65% from the company.
  • Year To Date – Since the the first trading session of this year CBAY has resulted in a return on investment of -23.13%.
  • Full Year – Lastly, in the past year, we’ve seen performance that comes to -53.06% out of CBAY. Over this period, the stock has sold at a high price of -59.67% and a low price of -4.12%.

Rations That Investors Should Consider

Digging into a few key ratios associated with a stock can provide traders a view of how dangerous and/or rewarding a an investment option may be. Here are a few of the most important ratios to think about when digging into CBAY.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the value of the stock is going to go down. Throughout the sector, biotech stocks tend to carry a higher short ratio. However, we also tend to see a lot of short squeezes in the space. Nonetheless, as it relates to CymaBay Therapeutics, Inc., the stock’s short ratio is 6.76.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure the company’s abilities to pay for its debts when they mature with only current assets or quick assets. In the biotechnology space, several companies are heavily reliant on continued investor support, these ratios can look upsetting. Nonetheless, quite a few gems in the biotechnology space do have good quick and current ratios. When it comes to CBAY, the quick and current ratios add up to 18.70 and 18.70 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the share price. when it comes to CymaBay Therapeutics, Inc., the book to share value ratio is 4.16.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re looking into a biotechnology stock, this is a very important ratio to think about. As it relates to CBAY, the cash to share value ratio comes to 3.89.

How Analysts Feel About CymaBay Therapeutics, Inc.

Although it’s rarely a good idea to unknowingly follow the thoughts of analysts, it is a good idea to use their opinions in order to validate your own thoughts before making an investment decision in the biotechnology space. Here are the most recent moves that we have seen from analysts when it comes to CBAY.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-14-19 Initiated Citigroup Buy $21
Feb-06-19 Initiated B. Riley FBR Neutral $9
Jun-28-18 Initiated Raymond James Outperform
Jun-06-18 Reiterated H.C. Wainwright Buy $21 → $23
Feb-13-18 Initiated Evercore ISI Outperform

Is Big Money Interested In CymaBay Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CBAY, here’s what we’re seeing:

Institutions own 98.90% of the company. Institutional interest has moved by 17.59% over the past three months. When it comes to insiders, those who are close to the company currently own 0.30% percent of CBAY shares. Institutions have seen ownership changes of an accumulative -41.37% over the last three months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 68.04M shares of CymaBay Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CBAY has a float of 63.99M.

It’s also important to take a look at the short float. After all, when a large portion of the float is sold short, the overall feeling in the market is that the equity is headed for a deep dive. With regard to CBAY, the percentage of the float that is currently being sold short sits at 11.20%. Most investors would say that a concerning short percent of the float is anything over 40%. Nonetheless, I’ve seen that a short ratio over 26% is probably going to be a play that comes with hefty risk.

Earnings

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.61. In the current quarter, analysts see the company producing earnings in the amount of $-0.36. Over the last 5 years, CBAY has generated revenue in the amount of $0 with earnings coming in at -15.50%. On a quarter over quarter basis, earnings have seen movement of -17.90% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings actually play an important role in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at information? If so, write a comment below and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here